In vivo terminal myeloid differentiation in patients treated with quizartinib. (A) Graph of peripheral total WBC count, absolute neutrophil count (ANC), and absolute blast count in a representative patient (Table 1 patient 2) during the first 2 months of treatment with quizartinib. (B) Photomicrograph of a peripheral blood neutrophil from a whole blood sample collected from the patient shown in panel A on day 35 of treatment. (C) BM aspirates collected from a representative patient (Table 1 patient 7) 1 week before and on days 15 and 29 of treatment with quizartinib. (D) Flow cytometry analysis of BM aspirate specimens collected pretreatment and on days 15 and 29 from patient 7. The analysis was performed on the day of collection, and the dot plots are overlaid, organized by color.